Medical Summaries and Commentaries™: Update from San Francisco: Interpreting Therapeutic Advancements for Severe Asthma

Released On
March 29, 2019

Expires On
March 29, 2020

Media Type

Completion Time
75 minutes

Pulmonology, Allergy & Immunology, Integrative Medicine, Occupational Medicine, Otolaryngology , Primary Care

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians' Education Resource®, LLC.

Supported by an educational grant from GlaxoSmithKline.

Credit Available

  • Physicians — maximum of 1.25 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is directed toward healthcare professionals specializing in immunology, allergy, pulmonology, primary care, and others interested in the care of patients with asthma.

Program Overview

This online activity is designed to update physicians on data presented at the American Academy of Allergy, Asthma, & Immunology (AAAAI) Annual Meeting, held in February 2019 in San Francisco, CA. PER’s Medical Summaries and Commentaries™: Update from San Francisco: Interpreting Therapeutic Advancements for Severe Asthma online CME activity facilitates critical assessment and clinical integration of new evidence when appropriate. The activity reviews 8 abstracts with some of the most compelling and clinically relevant severe asthma presentations from the meeting. For each abstract, a short summary of key clinical data is accompanied by expert perspective that provides insight into how clinicians can apply these findings to their clinical practice to improve patient care.

Benefits of Participation

  • Learn about emerging treatments for the management of severe asthma
  • Hear about digital asthma programs that may improve management of severe asthma
  • Learn about new research findings with approved biologic treatments for severe asthma
  • Explore future directions for the prevention and management of exacerbations in severe asthma
  • Be informed about recent clinical trials in severe asthma and their impact on clinical practice decisions

Learning Objectives

After successful completion of this activity, you should be better prepared to:

  • Explain recent clinical trial findings on burden and phenotypes of asthma
  • Integrate evidence-based diagnostic and therapeutic recommendations and therapeutic implications of new and emerging data into practice
  • Incorporate best practices for effective management of patients with uncontrolled asthma based on new and emerging data


Michael S. Blaiss, MD

Clinical Professor of Pediatrics
Medical College of Georgia at Augusta University
Augusta, GA

Lila Kertz, MSN, RN, CPNP, AE-C

Pediatric Nurse Practitioner
Clinical Director, Severe Asthma Clinic for Kids
Pediatric Allergy, Immunology, and Pulmonary Medicine
Washington University School of Medicine
Saint Louis Children’s Hospital
St. Louis, MO

Accreditation Statement

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The following contributors have relevant financial relationships with commercial interests to disclose:

Michael S. Blaiss, MD

  • Consultant: Sanofi/Regeneron

Lila Kertz, MSN, RN, CPNP, AE-C

  • Speakers Bureau: Sanofi, AstraZeneca

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade) and program evaluation. Certificates can be printed immediately.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the company that provided commercial support for this activity.